102 studies found for:    daclizumab
Show Display Options
Rank Status Study
1 Completed
Has Results
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Conditions: Anterior Uveitis;   Arthritis, Juvenile Idiopathic;   Iritis;   Immunosuppression
Intervention: Drug: Daclizumab
2 Recruiting Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma
Conditions: Hodgkin Disease;   Hodgkin Lymphoma
Interventions: Radiation: 111In-daclizumab;   Radiation: 90Y-daclizumab
3 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab
4 Completed
Has Results
Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Choroidal Neovascularization
Interventions: Drug: Intravenous Daclizumab;   Drug: Intravenous Infliximab;   Other: Observation;   Drug: Oral Rapamycin
5 Completed Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
Condition: Renal Transplantation
Interventions: Drug: Thymoglobulin (ATG);   Drug: Daclizumab
6 Completed Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
Condition: HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)
Intervention: Drug: CHOP-daclizumab
7 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab
8 Completed A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Condition: Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Intervention: Drug: Daclizumab
9 Active, not recruiting Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Biological: Daclizumab High Yield Process (DAC HYP) (Active);   Drug: Interferon beta-1a Placebo;   Biological: Interferon beta-1a (IFN β-1a) (Active);   Drug: Daclizumab High Yield Process Placebo
10 Completed Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
11 Completed Safety and Efficacy Study of Daclizumab High Yield Process to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Biological: Daclizumab High Yield Process;   Other: placebo
12 Completed Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
13 Completed Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
14 Completed Daclizumab and Sirolimus to Treat Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
15 Completed Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
Condition: Non-Infectious Intermediate and Posterior Uveitis
Intervention: Drug: Daclizumab
Condition: Uveitis
Intervention: Drug: Daclizumab (Zenapax)
17 Completed
Has Results
Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
Conditions: Kidney Diseases;   Kidney Transplantation;   Kidney Transplant;   Renal Transplantation;   Renal Transplant
Interventions: Drug: Daclizumab;   Drug: Mycophenolate mofetil (MMF);   Drug: Prednisone;   Drug: Tacrolimus;   Drug: Ganciclovir;   Drug: Valganciclovir;   Drug: Trimethoprim and sulfamethoxazole
18 Completed Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
Condition: Graft vs Host Disease
Intervention: Drug: daclizumab, infliximab
19 Completed To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
Condition: Psoriasis
Interventions: Drug: Daclizumab;   Drug: Cyclosporine;   Drug: cyclosporine and Daclizumab
20 Unknown  A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
Conditions: Aplastic Anemia;   Pure Red Cell Aplasia;   Diamond Blackfan Anemia
Interventions: Drug: Daclizumab;   Drug: Daclizumab (Zenapax)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years